Genera Biosystems receives TGA approval for its PapType HPV detection and genotyping test

25-Jan-2010 - Australia

Genera Biosystems announced that the Australian Therapeutic Goods Administration (TGA) has approved the entry of the company’s PapType Human Papillomavirus (HPV) test kit onto the Australian Register of Therapeutic Goods (ARTG). The company is now permitted to supply PapType to Australian customers, subject to the terms of the licence.

“This is a very significant, and tremendously satisfying achievement for everyone associated with our company” commented chairman, Mr. Fernando Careri. “To have taken a technological concept, and turned it into a product which will contribute to the health and well being of Australian women is something of which we should be extremely proud. Genera is already engaged in broad commercial discussions, and will now also engage in discussions with women’s health specialists around the country to investigate how PapType might be incorporated into national cervical cancer screening guidelines”.

Other news from the department research and development

More news from our other portals

Recognise, understand, heal: The World of Diagnostics